Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Morning chronotype and exercise associated with reduced ALS risk

25

Feb 2026

Morning chronotype and exercise associated with reduced ALS risk

Being an early bird, also called a morning person, and being more physically active are associated with lower risks of amyotrophic lateral sclerosis (ALS), according to a preliminary study released February 25, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

Prior COVID infection increases kidney disease risk

25

Feb 2026

Prior COVID infection increases kidney disease risk

Approximately one in seven adults in the United States has kidney disease, where the organs responsible for filtering waste and excess water from the blood are damaged, according to the Centers for Disease Control and Prevention.

COVID-19 initially reduced asthma attacks but widened socioeconomic disparities, study finds

25

Feb 2026

COVID-19 initially reduced asthma attacks but widened socioeconomic disparities, study finds

A large retrospective study of more than 162,000 asthma patients in the Bronx found that asthma exacerbations dropped sharply after the onset of COVID-19 before rebounding in children but remaining lower in adults. Socioeconomic disparities widened during the pandemic, particularly among Medicaid recipients, certain income groups, and patients with documented unmet social needs, while racial and ethnic gaps persisted without significantly expanding.

Meningococcal B vaccine fails to prevent gonorrhea, trial shows

25

Feb 2026

Meningococcal B vaccine fails to prevent gonorrhea, trial shows

Contrary to existing evidence from observational studies, the meningococcal B vaccine (4CMenB) has no effect on preventing the acquisition of gonorrhea, according to the results of the world's largest randomized control trial (RCT) into possible efficacy, conducted by Griffith University's Institute for Biomedicine and Glycomics and the Kirby Institute at UNSW Sydney.

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

25

Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.